€114.40
0.44% today
Paris, Sep 09, 05:35 pm CET
ISIN
FR0013280286
Symbol
BIM

bioMerieux SA Stock price

€114.40
-10.20 8.19% 1M
-3.20 2.72% 6M
+10.90 10.53% YTD
+4.10 3.72% 1Y
+22.34 24.27% 3Y
-5.50 4.59% 5Y
+80.97 242.17% 10Y
+100.73 737.07% 20Y
Paris, Closing price Tue, Sep 09 2025
+0.50 0.44%
ISIN
FR0013280286
Symbol
BIM

Key metrics

Basic
Market capitalization
€14.0b
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
35.9 | 25.0
P/S
3.4 | 3.3
EV/Sales
- | -
EV/FCF
-
P/B
-
Dividends
DPS
€0.90
Yield 1Y | 5Y
0.8% | 0.8%
Growth 1Y | 5Y
5.9% | 36.5%
Payout 1Y | 3Y
24.7% | 24.8%
Increased
1 Year
Financials (TTM | estimate)
Revenue
€4.1b | €4.3b
EBITDA
€713.6m | €1.0b
EBIT
€509.7m | €701.2m
Net Income
€377.9m | -
Free Cash Flow
€439.4m
Growth (TTM | estimate)
Revenue
8.3% | 7.8%
EBITDA
14.3% | 57.1%
EBIT
-1.9% | 14.6%
Net Income
-8.1% | -
Free Cash Flow
181.0%
Margin (TTM | estimate)
Gross
56.3%
EBITDA
17.3% | 23.7%
EBIT
12.4%
Net
9.2% | -
Free Cash Flow
10.7%
Financial Health
Equity Ratio
72.9%
Return on Equity
10.3%
ROCE
-
ROIC
-
Debt/Equity
-
More
EPS
€3.2
FCF per Share
-
Short interest
-
Employees
14k
Rev per Employee
€280.0k
Show more

Is bioMerieux SA a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.

bioMerieux SA Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a bioMerieux SA forecast:

11x Buy
61%
6x Hold
33%
1x Sell
6%

Analyst Opinions

18 Analysts have issued a bioMerieux SA forecast:

Buy
61%
Hold
33%
Sell
6%

Financial data from bioMerieux SA

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
4,122 4,122
8% 8%
100%
- Direct Costs 1,802 1,802
7% 7%
44%
2,319 2,319
9% 9%
56%
- Selling and Administrative Expenses 1,130 1,130
7% 7%
27%
- Research and Development Expense 500 500
5% 5%
12%
714 714
14% 14%
17%
- Depreciation and Amortization 204 204
95% 95%
5%
EBIT (Operating Income) EBIT 510 510
2% 2%
12%
Net Profit 378 378
8% 8%
9%

In millions EUR.

Don't miss a Thing! We will send you all news about bioMerieux SA directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

bioMérieux SA engages in the provision of in vitro diagnostic solutions, which determine the source of disease and contamination. The firm develops testing. detection, and other laboratory system for the analysis of cancer, diseases, and infections caused by bacteria, virus, and fungi. The company was founded Alain Mérieux in 1963 and is headquartered in Marcy l'Etoile, France.

Head office France
CEO Pierre Boulud
Employees 14,451
Founded 1967
Website www.biomerieux.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today